3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Endocrine
1
Conditions
Breast Neoplasms
2
Neoplasms by Site
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Breast Diseases
1
Advanced Metastatic Breast Cancer
1
Interventions
pembrolizumab
44
Carboplatin
40
Cisplatin
36
Paclitaxel
29
Pemetrexed
24
Nivolumab
24
Gemcitabine
23
Dexamethasone
21
Rituximab
18
Ipilimumab
16
Cyclophosphamide
15
Fluorouracil
14
Capecitabine
14
atezolizumab
13
Docetaxel
13
trastuzumab deruxtecan
12
Trastuzumab
12
Lenalidomide
12
durvalumab
11
daratumumab
11
Cytarabine
11
olaparib
10
Prednisone
10
Bortezomib
10
Bevacizumab
10
130-nm albumin-bound paclitaxel
10
Doxorubicin
9
venetoclax
8
Oxaliplatin
8
Crizotinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Has announcements
×
ribociclib
×
Clear all
NCT03701334
2026-04-01
NATALEE
Novartis
Phase 3
Active not recruiting
5,101 enrolled
1 FDA
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA